Clinical predictive factors of the efficacy of immune checkpoint inhibitors and kinase inhibitors in advanced hepatocellular cancer

医学 内科学 肝细胞癌 肿瘤科 联合疗法 癌症 胃肠病学 人口 肝癌 环境卫生
作者
Yunyun Lu,Yi Lu
出处
期刊:Clinical & Translational Oncology [Springer Science+Business Media]
标识
DOI:10.1007/s12094-024-03644-9
摘要

Abstract Background Hepatocellular carcinoma (HCC) is a highly aggressive tumor associated with significant morbidity and mortality rates. Combination therapy with immune checkpoint inhibitors (ICIs) and kinase inhibitors has emerged as a promising strategy for liver cancer treatment in recent years. However, the clinical factors predicting the outcomes of combination therapy in patients with advanced liver cancer remain uncertain. Therefore, this study investigated the relationships between clinical predictors and the efficacy of ICI plus kinase inhibitor therapy to personalize treatment plans. Methods We retrospectively enrolled 98 patients who received combination treatment with ICIs and kinase inhibitors for advanced HCC. Based on blood lipid levels and other clinical factors prior to treatment, we investigated potential biomarkers that could predict treatment responses in this patient population. Results Mean progression-free survival (PFS) and overall survival (OS) in this cohort were 10.1 and 17.2 months, respectively. Via multivariate analysis, the absence of extrahepatic metastasis, the absence of portal vein thrombosis (PVT), neutrophil-to-lymphocyte ratio (NLR) < 3.225, platelet-to-lymphocyte ratio (PLR) < 140.75, and prognostic nutritional index (PNI) ≥ 37.25 were identified as independent predictors of improved PFS. Factors associated with better OS included PLR < 140.75 and total cholesterol (TC) < 3.46 mmol/L. Univariate analysis identified significant associations of Eastern Cooperative Oncology Group performance status (ECOG PS), hepatitis B virus (HBV) DNA levels, Child–Pugh classification, alpha-fetoprotein (AFP), TC, and the receipt of regorafenib with PFS. Additionally, ECOG PS, Child–Pugh classification, AFP, PVT, NLR, PNI, and the receipt of regorafenib were significantly associated with OS. Conclusions PLR and TC were potential clinical predictive factors for survival outcomes in patients with advanced HCC who received ICI/kinase inhibitor combination therapy. It is important to know the clinical characteristics of patients prior to treatment initiation to optimize outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
粥粥爱糊糊完成签到,获得积分10
刚刚
yyw完成签到,获得积分10
刚刚
mixieerjieke完成签到,获得积分10
1秒前
1秒前
Lars完成签到,获得积分10
1秒前
2秒前
2秒前
翻斗花园壮壮完成签到,获得积分10
2秒前
CrazyLion完成签到,获得积分10
2秒前
星空发布了新的文献求助10
3秒前
LL完成签到 ,获得积分10
4秒前
公主关注了科研通微信公众号
4秒前
4秒前
数据线完成签到 ,获得积分10
4秒前
july7292发布了新的文献求助10
4秒前
冷艳的语薇完成签到,获得积分10
5秒前
山东老铁完成签到,获得积分10
5秒前
zzzz完成签到 ,获得积分10
5秒前
风吹麦浪的应助被顶刊相见采纳,获得10
5秒前
桃枝气泡完成签到 ,获得积分10
6秒前
lucky完成签到 ,获得积分10
6秒前
阳光完成签到,获得积分10
6秒前
蚂蚁完成签到,获得积分10
6秒前
加薪完成签到,获得积分10
6秒前
6秒前
云水别行客完成签到,获得积分10
6秒前
pauline完成签到,获得积分10
7秒前
htt完成签到,获得积分10
7秒前
yanjia的应助被机制的呆呆采纳,获得30
7秒前
yy完成签到,获得积分10
7秒前
迷路元菱完成签到,获得积分10
7秒前
azure完成签到 ,获得积分10
8秒前
NAN发布了新的文献求助10
8秒前
8秒前
鑫渊完成签到,获得积分10
8秒前
潮湿小兰花完成签到,获得积分10
8秒前
8秒前
丘比特的应助被daigang采纳,获得10
9秒前
XwK完成签到,获得积分10
9秒前
绣九完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162